Virax Biolabs Group Ltd. Class A (VRAX) Stock Statistics & Valuation Metrics

Virax Biolabs Group Ltd. Class A has a market cap or net worth of $1.61M. The enterprise value is -$2.07T.

Market Cap

$1.61M

Enterprise Value

-$2.07T

Virax Biolabs Group Ltd. Class A has 1,344,988 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,344,988

Owned by Insiders

―

Owned by Institutions

4.41%

Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -70.05%.

Return on Equity (ROE)

-0.66

Return on Assets (ROA)

-0.60

Return on Invested Capital (ROIC)

-70.05%

Return on Capital Employed (ROCE)

-0.84

Revenue Per Employee

477.808

Profits Per Employee

-193.22K

Employee Count

26

Asset Turnover

0.00

Inventory Turnover

0.10

The current PE Ratio of Virax Biolabs Group Ltd. Class A is -0.05. Virax Biolabs Group Ltd. Class A’s PEG ratio is -0.00.

PE Ratio

-0.05

PS Ratio

113.11

PB Ratio

0.06

Price to FCF

-0.20

Price to Operating Cash Flow

-0.06

PEG Ratio

-0.00

In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 12.42K and earned -5.02M in profits. Earnings per share was -12.64.

Revenue

12.42K

Gross Profit

7,690

Operating Income

-6.40M

Pretax Income

-5.93M

Net Income

-5.02M

EBITDA

-5.43M

Earnings Per Share (EPS)

-12.64

In the last 12 months, operating cash flow was -7.55M and capital expenditures -397,334, giving a free cash flow of -7.94M billion.

Operating Cash Flow

-7.55M

Free Cash Flow

-7.94M

Free Cash Flow per Share

-19.98

Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-509.08%

Earnings Yield

-1596.37%

Beta

2.08

52-Week Price Change

-90.77%

50-Day Moving Average

2.10

200-Day Moving Average

3.77

Relative Strength Index (RSI)

32.17

Average Volume (3m)

607.56K

Virax Biolabs Group Ltd. Class A upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date

Feb 02, 2023

Next Earnings Date

―

Ex-Dividend Date

―

Virax Biolabs Group Ltd. Class A as a current ratio of 9.97, with Debt / Equity ratio of 5.47%

Current Ratio

9.97

Quick Ratio

9.90

Debt to Market Cap

0.01

Net Debt to EBITDA

1.11

Interest Coverage Ratio

-103.60

In the past 12 months, Virax Biolabs Group Ltd. Class A has paid -900.24K in taxes.

Income Tax

-900.24K

Effective Tax Rate

0.15

Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.56, with an EV/FCF ratio of 0.56.

EV to Sales

-318.18

EV to EBITDA

0.56

EV to Free Cash Flow

0.56

EV to Operating Cash Flow

0.59

Virax Biolabs Group Ltd. Class A has $6.52M in cash and marketable securities with $414.39K in debt, giving a net cash position of $6.10M billion.

Cash & Marketable Securities

$6.52M

Total Debt

$414.39K

Net Cash

$6.10M

Net Cash Per Share

$4.54

Tangible Book Value Per Share

$18.45

Gross margin is -1480.46%, with operating margin of -64038.24%, and net profit margin of -52473.24%.

Gross Margin

-1480.46%

Operating Margin

-64038.24%

Pretax Margin

-60931.44%

Net Profit Margin

-52473.24%

EBITDA Margin

-57141.39%

EBIT Margin

-60270.31%

The average price target for Virax Biolabs Group Ltd. Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

96.22%

EPS Growth Forecast

58.99%